Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Capital Expenditures (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Capital Expenditures data on record, last reported at -$8.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 17871.11% year-over-year to -$8.0 million; the TTM value through Dec 2025 reached $1.2 million, up 870.25%, while the annual FY2025 figure was $1.2 million, 870.25% up from the prior year.
  • Capital Expenditures reached -$8.0 million in Q4 2025 per OCUL's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.0 million in Q3 2025 and bottomed at -$8.0 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $311000.0, with a median of $334000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: surged 15335.48% in 2023, then tumbled 17871.11% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $995000.0 in 2021, then skyrocketed by 116.08% to $2.2 million in 2022, then crashed by 111.67% to -$251000.0 in 2023, then skyrocketed by 117.93% to $45000.0 in 2024, then crashed by 17871.11% to -$8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$8.0 million in Q4 2025, $6.0 million in Q3 2025, and $1.2 million in Q2 2025.